Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent.Pfizer had said its two-shot vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries had already gone ahead with plans to give booster doses.
The drugmakers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months, adding that there were only five cases of COVID-19 in the booster group, compared with 109 cases in the group which received the placebo shot. "These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease," Pfizer CEO Albert Bourla said in a statement.
The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older. The companies said they would submit detailed results of the trial for peer-reviewed publication, to the U.S. Food and Drug Administration , the European Medicines Agency, and other regulatory agencies as soon as possible.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer vaccine is 93% effective in preventing Covid-19 hospitalization among adolescents, CDC study findsThe Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to Covid-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children age 12 to 15 and 94% effectiveness for those age 16 to 18.
Lire la suite »
Pfizer Vaccine 93% Effective At Preventing Hospitalization In Kids Ages 12-18More good news about the effectiveness of Pfizer’s COVID-19 vaccine in adolescents ages 12-18 — this time, about hospitalization rates The Centers for Disease Control and Prevention just rolled out new stats pointing to Pfizer’s COVID-19 vaccine being safe and effective at preventing hospitalization in kids ages 12-18. The CDC’s latest study shows that Pfizer’s […]
Lire la suite »
Can I get a COVID-19 vaccine booster shot? Here's who can get them and where.So far, 8.8 million Americans have received a booster dose of the Pfizer vaccine. Here’s everything to know about booster doses of all three vaccines.
Lire la suite »
FDA Recommends Boosters of Moderna and Johnson&Johnson-Janssen COVID-19 VaccinesThe decision means boosters are authorized for all three COVID-19 vaccines available in the US
Lire la suite »
FDA Approves Moderna And J&J Covid Booster Shots, Signs Off On Mix-And-Match Approach — Here’s Who Is EligibleAll three Covid-19 vaccines now have booster shots authorized — but eligibility for extra doses depends on the specific vaccine.
Lire la suite »
U.S. FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boostThe U.S. Food and Drug Administration on Wednesday authorized booster doses of the COVID-19 vaccines from Moderna Inc and Johnson & Johnson , and said Americans can choose a different shot from their original inoculation as a booster.
Lire la suite »